ライフサイエンスコーパス: paraprotein

1 ression, associated with a decrease in serum paraprotein.

2 was positively correlated with the level of paraprotein.

3 ecreted by the tumor cells and the IgG serum paraprotein.

4 s from all patients with HSP90-SUMO1-binding paraproteins.

5 monoclonal antibodies, immune complexes and paraproteins.

6 c method to identify the cognate antigens of paraproteins.

7 mplex and significantly reduces secretion of paraproteins.

8 rden of clonal plasma cells that produce the paraproteins.

9 enged because of low detection of monoclonal paraproteins.

10 s (1.9 years) than patients with IgA and IgG paraproteins (2.3 and 2.5 years, respectively) (P < .001

11 D patients had lower frequency of detectable paraproteins (31% versus 92%, P = 0.004) and hematologic

12 D patients had lower frequency of detectable paraproteins (31% vs. 92%, P=0.004) and hematologic neop

13 collections, staging, serial serum and urine paraprotein analysis, serial PET-CT imaging, and a physi

14 tinuum that requires the presence of a serum paraprotein and differs in severity of skin lesions, ext

15 We have prospectively evaluated serial paraprotein and serum free light chain (FLC) measurement

16 Serum paraproteins and/or light chains or bone marrow biopsy d

17 experienced a greater than 50% reduction in paraprotein, and four (17%) of 24 patients entered compl

18 of 18 cases, the serum contained benign IgM paraproteins, and in four of these cases at least two Ig

19 Plasma cells producing high levels of paraprotein are dependent on the unfolded protein respon

20 increase in FLC both alone and with a whole paraprotein, as a result of a significantly shorter surv

21 pathy, multifocal motor neuropathy, and some paraprotein-associated demyelinating neuropathies.

22 Paraprotein-associated neuropathies are a diverse group

23 Paraproteins can cause a remarkably diverse set of patho

24 relationship between SFLCR normalization and paraprotein clearance.

25 onic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies.

26 thy, ophthalmoplegia, immunoglobulin M [IgM] paraprotein, cold agglutinins, and disialosyl antibodies

27 ntify subtle and layered patterns of corneal paraprotein deposition in PPK.

28 We found that paraproteins from a proportion of European, African-Amer

29 sumoylated and screened for reactivity with paraproteins from MGUS, MM, and WM patients.

30 E-MAP analysis of 2 MM paraproteins identified human cytomegalovirus (HCMV) as

31 ls in SCID-hu mice produced human monoclonal paraprotein (immunoglobulin M [IgM] and/or kappa or lamb

32 resulted in a greater than 25% reduction in paraprotein in 67% of patients, 13 patients (54%) experi

33 otein electrophoresis showed multiple clonal paraproteins in 4 of 5 cases.

34 chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL).

35 of disorders caused by direct deposition of paraproteins in the kidney.

36 of disorders caused by direct deposition of paraproteins in the kidney.

37 In three patients, all of whom had IgG-kappa paraproteins in their sera, the Abs were IgG-kappa.

38 in bands (APB), distinct from the presenting paraprotein, in 550 patients receiving high-dose therapy

39 physiology and the differential diagnosis of paraprotein-induced crystalline nephropathy.

40 50%-61%] vs 15% [IQR, 4%-50%]; P = .03) and paraprotein levels (median, 32.0 g/L [IQR, 24.0-48.0 g/L

41 was one complete response and a reduction in paraprotein levels and/or marrow plasmacytosis in eight

42 Reductions in the paraprotein levels were apparent within two months in 78

43 TGM1 cells, reduced serum myeloma-associated paraprotein levels, and better preservation of bone mine

44 th IgM AL amyloidosis have a significant IgM paraprotein (median, 10 g/L), less frequent lambda light

45 de in explaining the molecular mechanisms of paraprotein-mediated kidney injury.

46 Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% con

47 ented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC escape," respectively.

48 ectrophoresis (IFE), could be due to altered paraprotein production by the malignant plasma cell clon

49 cytic infiltrate in bone marrow (BM) and IgM paraprotein production.

50 4 of 520 patients who presented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC

51 lantation in the management of patients with paraprotein-related kidney disease continues to evolve.

52 tumumab-based regimen showed decreased serum paraproteins, resolution of ascites, and improved kidney

53 We first reconstruct the paraprotein's epitope by analyzing the peptides that str

54 We observed inhibition of serum paraprotein secretion, inhibition of tumor growth, and i

55 SUMO1 carriers produced HSP90-SUMO1-specific paraproteins, suggesting that sumoylated HSP90 promotes

56 we identified a posttranslationally modified paraprotein target (paratargs) in monoclonal gammopathie

57 es reduced tumor load assessed by monoclonal paraprotein titers, prevented splenomegaly, limited deve

58 Protein and nucleotide sequencing of the paraproteins' variable regions revealed 2 predominant Vl

59 The median IgM paraprotein was 8 g/L and serum free light chain (FLC) r

60 An immunoglobulin M (IgM) kappa paraprotein was detected in 86%; the remainder had IgM l

61 Stable disease (less than 25% reduction in paraprotein) was observed in an additional 2 (8%) patien

62 and reduction in levels of circulating human paraprotein were observed in mice treated with B-B4-DM1.

63 The serum or urine levels of paraprotein were reduced by at least 90 percent in eight

64 and in four of these cases at least two IgM paraproteins were present.

65 vious efforts to reconstruct the epitopes of paraproteins, with the significant difference that it pr